Compare SKYT & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYT | TYRA |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2021 | 2021 |
| Metric | SKYT | TYRA |
|---|---|---|
| Price | $32.31 | $30.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $19.40 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 2.5M | 581.6K |
| Earning Date | 02-25-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.62 | N/A |
| Revenue | ★ $346,587,000.00 | N/A |
| Revenue This Year | $28.48 | N/A |
| Revenue Next Year | $41.29 | N/A |
| P/E Ratio | $11.97 | ★ N/A |
| Revenue Growth | ★ 0.19 | N/A |
| 52 Week Low | $5.67 | $6.42 |
| 52 Week High | $36.27 | $31.56 |
| Indicator | SKYT | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 67.96 | 66.88 |
| Support Level | $29.80 | $27.40 |
| Resistance Level | $36.07 | $31.56 |
| Average True Range (ATR) | 3.24 | 2.01 |
| MACD | 0.15 | -0.11 |
| Stochastic Oscillator | 68.57 | 71.65 |
SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.